Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Biocardia, inc. save search
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
Published: 2024-03-12 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 5.58%
H: 2.85%
C: -14.27%
approval cell cardiamp heart therapy study
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 0.03%
H: 1.72%
C: -21.53%
biomarker positive cell cardiamp heart therapy results
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -3.19%
H: 7.01%
C: 2.35%
japan expected approval update cell cardiamp heart therapy
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 223.31%
H: 20.16%
C: -17.05%
fda approval cell cardiamp heart therapy
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -5.57%
H: 0.0%
C: -7.43%
cell cardiamp therapy
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -9.94%
H: 0.0%
C: -17.32%
cell cardiamp heart trial therapy results
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
Published: 2023-07-24 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -42.86%
H: 0.0%
C: -17.05%
cell cardiamp heart trial therapy
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
Published: 2023-07-05 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 1.53%
H: 5.26%
C: 3.38%
device cell system cardiamp heart medical therapy submission
BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
Published: 2023-06-20 (Crawled : 21:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 4.02%
H: 12.74%
C: 8.11%
fda review cell ongoing cardiamp heart therapy study
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
Published: 2023-05-23 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 0.59%
H: 1.17%
C: -1.18%
cell meeting cardiamp heart therapy study
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -2.22%
H: 3.18%
C: 0.0%
meeting cardiamp heart trial cardiology positive therapy
BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure
Published: 2022-08-24 (Crawled : 12:00) - biospace.com/
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 6.8%
H: 0.0%
C: -6.82%
enabling heart therapeutics agreement therapy
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial
Published: 2022-08-01 (Crawled : 12:20) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 7.59%
H: 0.0%
C: -7.69%
cardiamp heart trial therapy
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia
Published: 2022-07-12 (Crawled : 12:20) - globenewswire.com
SCPH | $4.57 0.22% 0.22% 110K
|
Health Technology
|
| O: 0.95%
H: 4.14%
C: -3.01%
MESO | $5.53 6.14% 5.44% 270K
|
Health Technology
|
| O: -2.52%
H: 3.8%
C: 1.48%
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -2.67%
H: 6.85%
C: 4.11%
heart therapy
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
Published: 2022-03-01 (Crawled : 13:30) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -1.87%
H: 4.76%
C: 4.29%
health heart trial cel therapy cardiamp
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed
Published: 2022-02-14 (Crawled : 13:00) - biospace.com/
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 2.02%
H: 0.0%
C: -14.04%
heart cel positive therapy cardiamp designation
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
Published: 2022-02-03 (Crawled : 13:30) - biospace.com/
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 24.84%
H: 17.86%
C: 2.04%
fda heart device system cel therapy cardiamp designation
BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: -1.02%
H: 4.32%
C: 1.38%
therapy trial cardiamp
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 1.02%
H: 4.54%
C: 3.72%
patent technology therapy
BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
BCDA P | $0.3678 2.17% -2.56% 67K
|
Health Technology
|
| O: 2.15%
H: 8.07%
C: 4.21%
heart therapy trial cardiamp
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.